Novel vaccines for broad protection against avian influenza

广泛预防禽流感的新型疫苗

• 批准号: 8228036
• 负责人: John K. Rose
• 金额: $ 40.55万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-15 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8228036
• 关键词: Address; Antibodies; Antibody Formation; Antigens; Attenuated; Avian Influenza; Avian Influenza A Virus; CD4 Positive T Lymphocytes; CD8B1 gene; Canada; Clinical Trials; Collaborations; Complement; Cytotoxic T-Lymphocytes; Data; Development; Effectiveness; Future; Genes; Goals; HIV vaccine; Health; Hemagglutinin; Hong Kong; Human; Immunity; Influenza; Influenza A Virus, H5N1 Subtype; Laboratories; Length; Life; Lung; Methods; Mus; Mutation; Passive Transfer of Immunity; Play; Population; Positioning Attribute; Proteins; Publishing; Recombinants; Role; Solid; T-Cell Depletion; Testing; Time; United States National Institutes of Health; Vaccine Production; Vaccines; Vesicular stomatitis Indiana virus; Virus; Virus Diseases; base; experience; influenza virus strain; influenza virus vaccine; influenzavirus; killings; neutralizing antibody; nonhuman primate; novel; novel vaccines; pandemic disease; pandemic influenza; research study; response; vector; vector vaccine; vector-based vaccine

DESCRIPTION (provided by applicant): Highly pathogenic avian influenza (HPAI) viruses are likely to cause an influenza pandemic at some point in the future. Traditional methods of influenza vaccine production will probably be too slow to allow an effective response to such a pandemic. Development of rapidly deployable vaccine platforms capable of protecting against such a pandemic is therefore of major importance. Vaccine vectors based on recombinant live, attenuated or replication- defective vesicular stomatitis virus (VSV) are among the most potent vaccine vectors tested to date. They also have a major advantage in that there is no pre-existing immunity to the vector in the human population. VSV vectors expressing an H5N1 hemmaglutinin (HA) protein from an HPAI virus induce high-titer broadly neutralizing (cross-clade) antibodies in both mice and non-human primates. They also protect against lethal AIV infection. The goal of the current project is to further develop and test novel, optimized, VSV-based AIV vaccine vectors that produce much higher levels of the AIV HA. These vectors should also induce much higher neutralizing antibody titers and are expected to generate maximal cross-clade neutralizing antibody titers to AIVs. The optimized, highly attenuated or replication-defective, single-cycle VSV vectors to be developed could form the basis for a broadly protective AIV vaccine that could be produced and deployed rapidly in response to an influenza virus pandemic. PUBLIC HEALTH RELEVANCE: Influenza pandemics in the 20th century are estimated to have killed more than 40 million people worldwide. Future pandemics will surely occur and are highly likely to result from mutation of avian influenza virus and crossover into the human population. The goal of this project is to develop a novel type of vaccine that elicits very broad neutralizing antibody and broad protection against avian influenza virus strains. In addition, unlike traditional influenza vaccines, this vaccine could be produced and deployed rapidly to halt a pandemic.

描述（由申请方提供）：高致病性禽流感（HPAI）病毒可能在未来某个时间点引起流感大流行。传统的流感疫苗生产方法可能太慢，无法有效应对这种大流行。因此，开发能够预防这种大流行病的可快速部署疫苗平台至关重要。基于重组活的、减毒的或复制缺陷型水疱性口炎病毒（VSV）的疫苗载体是迄今为止测试的最有效的疫苗载体之一。它们的另一个主要优势是，人类对该媒介没有预先存在的免疫力。表达来自HPAI病毒的H5N1血凝素（HA）蛋白的VSV载体在小鼠和非人灵长类动物中诱导高滴度的广泛中和（交叉进化枝）抗体。它们还可以防止致命的AIV感染。目前项目的目标是进一步开发和测试新型的、优化的、基于VSV的AIV疫苗载体，其产生高得多的AIV HA水平。这些载体还应诱导高得多的中和抗体滴度，并预期产生针对AIV的最大交叉进化枝中和抗体滴度。待开发的优化的、高度减毒的或复制缺陷的单循环VSV载体可以形成广泛保护性AIV疫苗的基础，该疫苗可以快速生产和部署以响应流感病毒大流行。公共卫生相关性：据估计，20世纪的流感大流行在全世界造成4000多万人死亡。未来的大流行肯定会发生，而且很可能是由于禽流感病毒变异并交叉进入人类群体。该项目的目标是开发一种新型疫苗，该疫苗可产生非常广泛的中和抗体，并对禽流感病毒株具有广泛的保护作用。此外，与传统的流感疫苗不同，这种疫苗可以快速生产和部署，以阻止大流行。